The earnings call highlighted strong clinical trial results, regulatory progress, and financial stability, indicating positive momentum for Kura Oncology's lead program, ziftomenib, and its pipeline. However, increased expenses and net loss present financial challenges. The sentiment is positive overall due to significant advancements and strong financial positioning.

Company Guidance

During the Second Quarter 2025 Kura Oncology financial results call, the company provided detailed guidance on their lead program, ziftomenib, and its potential impact on patients with acute myeloid leukemia (AML). Ziftomenib has shown promising results in the KOMET-001 trial with a CR/CRh rate of 23% in heavily pretreated relapsed/refractory NPM1-mutant AML patients. The FDA has accepted the new drug application for ziftomenib, granting it priority review with a PDUFA date set for November 30, 2025. Kura is preparing for commercialization in collaboration with Kyowa Kirin, anticipating a U.S. market potential of over $7 billion annually for menin inhibitors. The company is also focused on advancing its Phase III frontline trials under the KOMET-017 protocol, targeting up to 50% of AML patients. Additionally, Kura is progressing with its farnesyl transferase inhibitor, KO-2806, with three clinical abstracts accepted for presentation at the 2025 ESMO Congress. Financially, Kura reported collaboration revenue of $15.3 million from their Kyowa Kirin partnership for the second quarter of 2025, with $630.7 million in cash reserves, believed to be sufficient to fund operations into 2027.

Positive Data from KOMET-001 Trial

Ziftomenib showed promising results in relapsed or refractory NPM1-mutated AML with a CR/CRh rate of 23% and 63% of responders being MRD negative.

FDA Priority Review

FDA accepted the NDA for ziftomenib with a PDUFA target action date of November 30, 2025, indicating positive regulatory progress.

Strong Financial Position

Kura Oncology has $630.7 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into 2027.

Advancements in Pipeline

Progress with next-generation farnesyl transferase inhibitor, KO-2806, with three clinical abstracts accepted for presentation at the 2025 ESMO Congress.

Commercial Readiness for Ziftomenib

Preparations for potential approval are underway, including the building of commercial supply, quality systems, and a sales force.

Kura Oncology (KURA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KURA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.75 / -	-0.63	―	―	―
Aug 07, 2025	2025 (Q2)	-0.37 / -0.75	-0.59	-27.12% (-0.16)	―
May 01, 2025	2025 (Q1)	-0.60 / -0.66	-0.59	-11.86% (-0.07)	―
Feb 26, 2025	2024 (Q4)	-0.64 / -0.22	-0.55	60.00% (+0.33)
Nov 07, 2024	2024 (Q3)	-0.63 / -0.63	-0.5	-26.00% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.63 / -0.59	-0.53	-11.32% (-0.06)
May 02, 2024	2024 (Q1)	-0.55 / -0.59	-0.5	-18.00% (-0.09)
Feb 27, 2024	2023 (Q4)	-0.55 / -0.55	-0.49	-12.24% (-0.06)
Nov 02, 2023	2023 (Q3)	-0.54 / -0.50	-0.53	5.66% (+0.03)
Aug 03, 2023	2023 (Q2)	-0.54 / -0.53	-0.52	-1.92% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KURA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.96	$5.54	-7.05%
May 01, 2025	$6.49	$6.47	-0.31%
Feb 26, 2025	$7.77	$7.65	-1.54%
Nov 07, 2024	$17.77	$17.68	-0.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kura Oncology (KURA) report earnings?

Kura Oncology (KURA) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Kura Oncology (KURA) earnings time?

Kura Oncology (KURA) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KURA EPS forecast?

KURA EPS forecast for the fiscal quarter 2025 (Q3) is -0.75.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing